326 related articles for article (PubMed ID: 34607820)
1. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
2. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
[TBL] [Abstract][Full Text] [Related]
3. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
4. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
5. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
8. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
9. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract][Full Text] [Related]
11. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
12. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract][Full Text] [Related]
13. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
14. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
15. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
[TBL] [Abstract][Full Text] [Related]
16. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
[TBL] [Abstract][Full Text] [Related]
17. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
[TBL] [Abstract][Full Text] [Related]
19. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Elyashiv O; Ledermann J; Parmar G; Farrelly L; Counsell N; Feeney A; El-Khouly F; Macdonald I; Neto A; Arthur-Darkwa E; Burnett E; Jayson GC; Mileshkin L; Gourley C; Nicum S
Int J Gynecol Cancer; 2021 Jan; 31(1):134-138. PubMed ID: 33097567
[TBL] [Abstract][Full Text] [Related]
20. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR
J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
